Literature DB >> 17440633

The role of metabotropic glutamate receptors in drug reward, motivation and dependence.

Athina Markou1.   

Abstract

Addiction to drugs of abuse is a disorder that involves dysfunctions in motivational processes. Both the primary rewarding effects of drugs, as well as the acquired motivational properties of stimuli associated with drug-seeking and -taking, contribute to the perpetuation of dependence on drugs of abuse. Metabotropic glutamate (mGlu) receptors, which mediate slow glutamate neurotransmission, are located throughout limbic and cortical brain sites implicated in drug addiction. Preclinical evidence suggests that mGlu receptors play a crucial role in regulating behavioral effects of drugs of abuse relevant to drug addiction. Specifically, antagonists at excitatory postsynaptic mGlu5 receptors decrease drug self-administration without affecting motor behaviors, cognition or the reward value of natural rewards, while agonists at inhibitory presynaptic mGlu2/3 receptor agonists prevent reinstatement to drug-seeking and -taking after a period of abstinence. These findings have increased our understanding of the neuropathological processes associated with aspects of dependence on drugs of abuse and have provided new targets for pharmacological approaches to the treatment of dysfunctions in motivational processes characterizing the various phases of drug addiction.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17440633     DOI: 10.1358/dnp.2007.20.2.1083435

Source DB:  PubMed          Journal:  Drug News Perspect        ISSN: 0214-0934


  7 in total

Review 1.  Metabotropic Glutamate Receptors 2 and 3 as Targets for Treating Nicotine Addiction.

Authors:  Alan J Cross; Robert Anthenelli; Xia Li
Journal:  Biol Psychiatry       Date:  2017-11-21       Impact factor: 13.382

Review 2.  Basic/Translational Development of Forthcoming Opioid- and Nonopioid-Targeted Pain Therapeutics.

Authors:  Nebojsa Nick Knezevic; Ajay Yekkirala; Tony L Yaksh
Journal:  Anesth Analg       Date:  2017-11       Impact factor: 5.108

Review 3.  Metabotropic Glutamate Receptor 7 (mGluR7) as a Target for the Treatment of Psychostimulant Dependence.

Authors:  Xia Li; Athina Markou
Journal:  CNS Neurol Disord Drug Targets       Date:  2015       Impact factor: 4.388

Review 4.  Metabotropic glutamate 7 (mGlu7) receptor: a target for medication development for the treatment of cocaine dependence.

Authors:  Xia Li; Zheng-Xiong Xi; Athina Markou
Journal:  Neuropharmacology       Date:  2012-04-21       Impact factor: 5.250

5.  Modafinil blocks reinstatement of extinguished opiate-seeking in rats: mediation by a glutamate mechanism.

Authors:  Pouya Tahsili-Fahadan; Gregory V Carr; Glenda C Harris; Gary Aston-Jones
Journal:  Neuropsychopharmacology       Date:  2010-07-14       Impact factor: 7.853

Review 6.  Opioid and Psychostimulant Plasticity: Targeting Overlap in Nucleus Accumbens Glutamate Signaling.

Authors:  Matthew Hearing; Nicholas Graziane; Yan Dong; Mark J Thomas
Journal:  Trends Pharmacol Sci       Date:  2018-01-12       Impact factor: 14.819

7.  The role of group II metabotropic glutamate receptors in cognition and anxiety: comparative studies in GRM2(-/-), GRM3(-/-) and GRM2/3(-/-) knockout mice.

Authors:  Bianca De Filippis; Louisa Lyon; Amy Taylor; Tracy Lane; Philip W J Burnet; Paul J Harrison; David M Bannerman
Journal:  Neuropharmacology       Date:  2014-08-23       Impact factor: 5.250

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.